Related Experiment Video
Updated: Aug 17, 2026
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
Molecular aspects of pancreatic cancer and future perspectives
1Department of Visceral and Transplantation Surgery, University of Bern, Inselspital, Bern, Switzerland. helmut-friess@insel.ch
Abstract:
Pancreatic cancer has one of the worst prognoses of all human malignancies and the molecular mechanisms underlying this aggressive disease have been extensively investigated in the past years. Tyrosine kinase growth factor receptors and their ligands act to influence tumor cell growth, differentiation, invasion, metastasis, and angiogenesis. In pancreatic cancer a variety of these growth factor receptors and ligands are expressed at increased levels and this overexpression influences the clinical course of the disease. For example, the concomitant presence of the EGF receptor and its ligands EGF, TGF-alpha, and/or amphiregulin is associated with enhanced tumor aggressiveness and shorter survival periods following tumor resection. Furthermore, the growth inhibitory effects of the TGF-beta superfamily of serine-threonine kinase receptors and their ligands are often blocked in pancreatic cancer cells. In addition to these alterations, mutations of the p53 tumor-suppressor gene, the K-ras proto-oncogene, and the Smad4 gene are frequently present in these tumors. Taken together, the abundance of growth-promoting factors, the disturbance of growth inhibitory pathways, and the presence of gene mutations combine to give pancreatic cancer cells a distinct growth advantage which clinically results in rapid tumor progression and poor survival.
Insights
Pancreatic cancer is aggressive due to overexpressed growth factors and blocked inhibitory pathways. Gene mutations like p53 and K-ras further promote tumor growth, leading to poor patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Pancreatic cancer exhibits a poor prognosis, necessitating investigation into its aggressive molecular mechanisms.
- Growth factor signaling pathways, including tyrosine kinase receptors, significantly impact tumor progression.
- Aberrant signaling in pancreatic cancer involves both overexpressed growth factors and impaired inhibitory pathways.
Purpose of the Study:
- To investigate the molecular mechanisms driving pancreatic cancer aggressiveness.
- To understand the role of growth factor receptors and their ligands in pancreatic cancer.
- To identify key genetic alterations contributing to poor prognosis in pancreatic cancer.
Main Methods:
- Review of existing literature on molecular mechanisms in pancreatic cancer.
- Analysis of the expression and function of growth factor receptors and ligands.
- Examination of common gene mutations (p53, K-ras, Smad4) in pancreatic tumors.
Main Results:
- Overexpression of epidermal growth factor receptor (EGF receptor) and its ligands correlates with increased tumor aggressiveness and reduced survival.
- Growth inhibitory signaling pathways, such as those involving the TGF-beta superfamily, are frequently inactivated in pancreatic cancer.
- Frequent mutations in tumor-suppressor genes (p53) and oncogenes (K-ras) are observed, alongside Smad4 gene alterations.
Conclusions:
- The combination of abundant growth-promoting factors, disrupted growth inhibition, and genetic mutations confers a significant growth advantage to pancreatic cancer cells.
- These molecular alterations collectively result in rapid tumor progression and poor patient survival.
- Targeting these pathways presents potential therapeutic strategies for pancreatic cancer.
